Miguel Galán

7PUBLICATIONS
51CO-AUTHORS
Innate immunityPredictive and prognostic markersCardiology (incl. cardiovascular diseases)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Nov 25, 2025
pDCs amplify tissue-resident memory CD8+ T cell responses during viral reinfection.

Elena Hernández-García, Miguel Galán, Sofía C Khouili

|Jul 16, 2025
Imidazole propionate is a driver and therapeutic target in atherosclerosis.

Annalaura Mastrangelo, Iñaki Robles-Vera, Diego Mañanes

|May 30, 2025
cDC1s Promote Atherosclerosis via Local Immunity and Are Targetable for Therapy.

Miguel Galán, Laura Fernández-Méndez, Vanessa Núñez

|Oct 07, 2021
miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer.

Alicia Romero-Lorca, Apolonia Novillo, María Gaibar

|Feb 12, 2021
Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer.

María Gaibar, Miguel Galán, Alicia Romero-Lorca

Pageof 2